Online Supplement

Inclusion Criteria

a) Men and women ages 28 to 65

b) Healthy volunteers with no psychiatric history (mental illnesses included in ICD 10 F0.X - F99.X)

c) No family history of psychotic disorders up to second-degree relatives

Exclusion Criteria:

a) Pregnancy

b) Intracranial hypertension, arterial hypertension or pulmonary hypertension

- c) Stroke
- d) Congestive heart failure
- e) Pacemaker
- f) Metal clamp in the head and/or face
- g) Celiac disease
- h) Left-handedness

i) Usage of any medication on daily basis except for contraception

j) Person in dependent position - students of medical faculties

k) Person in dependent position – students of other faculties younger than 28

Criteria for premature termination of participation in this study:

a) Participant can cancel his participation anytime without giving any reason

b) Changes in health state including use of pharmacological substances

c) Changes in psychic state including traumatic events last 3 months (eg. death in family etc.)

d) Pregnancy

e) Significant side effects that are related to assessments in this study

		DED	OBN	VRS	G-ASC
	psilocybin	28.7 (14.1)	58.9 (23.8)	60.1 (20.9)	45,3 (19)
EEG	placebo	2.89 (5.32)	6.05 (11.6)	3 (8.08)	3.95 (7.38)
	F (1,37)	142.86	170.32	245.25	271.09
	psilocybin	29.1 (16.3)	55.6 (27.5)	60.9 (23.9)	44.8 (17.5)
fMRI	placebo	1.74 (3.27)	2.49 (4.08)	1.44 (2.78)	1,89 (3)
	F (1,24)	59.81	88.76	185.36	132.01

Altered state of consciousness scale (ASCs)

Table 2: ANOVA showed a significant main effect of treatment for each subscale of ASCs (mean, SD, and F values above) in both study arms. There were no significant effects of between-subjects variables (sex, experience) or interactions.

Persisting effects Questionaire (PEQ)

		Attitudes about life	Attitudes about self	Mood changes	Behavior changes	Altruistic/positiv e social effects	Increased spirituality
	psilocybin	39.1 (22.2)	34.5 (21.9)	32.3 (23.6)	27.2 (21.2)	31.3 (25.5)	28.2 (24.1)
EEG	placebo	10.7 (14.9)	9.6 (15.9)	7.52 (11.9)	7.24 (13.3)	6.15 (17.3)	8.79 (19)
	F (1,37)	55.31	46.62	41.78	24.91	39.30	28.7
	psilocybin	30.9 (24.4)	26.4 (22.8)	25.3 (24.3)	22.7 (21.6)	24.6 (26.1)	24.8 (25)
fMRI	placebo	8.52 (19.1)	7.92 (16.8)	8.02 (18.6)	7.38 (16.3)	9.29 (22.1)	8.25 (18.6)
	F (1,24)	16.04	12.97	10.71	8.94	13.05	8.99


Table 3: ANOVA showed a significant main effect of treatment for each positive subscale of PEQ (mean, SD, and F values above) in both study arms. There were no significant effects of between-subjects variables (sex, experience) or interactions. We did not observe any difference in negative subscales.

Placebo responders and psilocybin non-responders, detailed characteristics of individuals

											Psilocin plasma levels (ng/ml)			
	Sex (M/F)	age range	weigh (kg)	dose (mg)	experienced (E) /naive (N)	mental healthcare proffesional (M) / other (O)	EEG/fMRI	session	G-ASC	PEQ positive average	60 min	120 min	240 min	360 min
	м	31-35	75	19	E	0	EEG	1 st	33.38	25.82	n.d.	n.d.	n.d.	n.d.
	F	36-40	56	16	N	ο	EEG	1 st	13.24	10.1	n.d.	n.d.	n.d.	n.d.
PLA responders	F	26-30	67	18	N	ο	EEG	2 nd	32.04	38.99	n.d.	n.d.	n.d.	n.d.
	F	26-30	65	17	Ν	М	EEG	2 nd	7.89	16.65	n.d.	n.d.	n.d.	n.d.
	F	46-50	67	17	Ν	0	EEG	1 st	0	0.26	NA	23	26	17
	F	26-30	60	16	E	м	EEG	1 st	17.96	57.34	10	12	10	6
PSI non-responder	м	26-30	72	19	E	ο	EEG	2 nd	12.18	0	NA	NA	NA	NA
or low responder	М *	36-40	77	20	E	м	EEG	2 nd	20.72	1.03	24	25	14	7
	м	31-35	56	16	E	ο	fMRI	1 st	19.15	21.18	NA	NA	NA	NA
	М*	36-40	79	20	E	м	fMRI	1 st	20.1	11.05	28	12	5	3

* identical subject

Table 4. Characteristics of placebo responders and psilocybin non-responders or mild responders based on ASCs. Placebo respondent's scores equal to the psilocybin group average and/or (scores above Q3 + 1.5 * IQR) on all ASCs scales. Non-responders scores equal to placebo average and/or scores below Q1 - IQR on 3 out of 4 ASCs scales. PEQ positive average is an average of positive items on the PEQ scale. *n.d.* = *not detected, NA* = *not available.*



Visualisation of VAS scale on emotional valence with psilocin levels and Peak + last point and correlations

Figure 5. (**A**, **C**) visualisation of VAS scale on emotional valence with psilocin levels measured by (GC/MS and/or LC/MS) in EEG and fMRI arms. (**B**) schematic visualisation of peak + last point hypothesis. Below are correlations of ASCs and PEQ subscales with the "maximum positive peak + last score" within EEG arm (**D**) and fMRI arm (**E**). *Shown P values are uncorrected*)